The Board of Pharmacy met last week and held a rulemaking hearing on the Compounding and Ambulatory Surgery Treatment Center (ASTC) Pharmacy rules, as well as standard Board business.  

• The Board approved its first petition to remove consent orders related to substance use from public view on a pharmacist's profile on the Licensure Verification tool. This is in accordance with Public Chapter 100. A rulemaking hearing is occurring later this month related to this process.  

• The Board approved the proposed rules for Compounding and ASTC Pharmacy with amendments. The Board voted to approve a 12-month educational period following final approval of the rules by the Secretary of State where compounding pharmacies may work towards compliance. If you have questions about which specific amendments were made, please contact olivia@tnpharm.org. 

• The Board's Rulemaking Committee reported at their recent meeting that it plans to have a draft of updated rules by December 2026. At the next Rulemaking Committee meeting on April 30, the committee will focus on at least license reinstatement and pharmacy technicians, while the May 21 meeting will focus on workplace conditions. 

Fees for certain licensure categories will be changing. The Board is still working to finalize these new fees. 

Also in Tennessee, the Department of Health Vaccine-Preventable Diseases and Immunization Program (VPDIP) invites you to the 4th Annual Immunization Provider Expo, taking place virtually on April 14. The Expo will run from 8:00 am to 12:00 noon CST. This year's theme, "Restoring Trust in Vaccines", highlights how emotional storytelling, community engagement and data-driven insights can help rebuild public confidence in immunizations.  

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

The Department of Health (TDH) continues to closely monitor respiratory syncytial virus (RSV) activity across the state. Recent emergency department data indicates that RSV activity remains elevated but has begun decreasing in Tennessee. Due to continued RSV activity in the state, pediatric providers and hospitals may continue to administer RSV immunizations to eligible infants through April 30. RSV immunizations remain available for ordering through TennIIS for the Vaccines for Children (VFC) program.  

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

Tennessee Pharmacy Association's advocacy team has developed a comprehensive, user-friendly set of responses addressing the most common misinformation surrounding SB 2040 (Harshbarger) and HB 1959 (Scarbrough). This resource is intended to equip members with clear, accurate messaging to confidently respond to misleading claims, particularly those circulating on social media about the bills' intent and impact. Members are encouraged to use these prepared responses when engaging in online discussions or conversations where misinformation appears, helping ensure consistent, fact-based communication.  

Also, Tennessee patients and pharmacists who have received unwanted texts, calls or app restrictions related to lobbying efforts can report these concerns to the Tennessee Attorney General. Using pharmacy communication channels for political advocacy may violate consumer protection laws and health privacy laws, and filing a complaint helps ensure these practices can be investigated and addressed. To submit a report, use the official Attorney General complaint form.  

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

The Department of Commerce and Insurance’s new audit of CVS Caremark details extensive violations of the state’s PBM laws, which spans discriminatory reimbursement, banned spread pricing and appeals noncompliance. CVS Caremark has 30 days to comply with the findings, after which the matter will be referred to legal services. The Tennessee Pharmacy Association issued this statement of the findings. 

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

The Department of Health recently released a “Dear Colleague” provider communication highlighting recent changes to the hepatitis B vaccine recommendations. Specifically, this communication emphasizes the severity of hepatitis B infection for infants and adolescents, as well as how hepatitis B often goes undiagnosed, which leads to a delay in treatment.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

This notice is to inform you of changes to the TennCare pharmacy program. We encourage you to read this thoroughly and contact OptumRx’s Pharmacy Support Center (866-434-5520) should you have additional questions. 

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

TennCare has made updates to Obesity and Oncology drug management. GLP-1 prior authorizations will remain active for one year with no changes to the criteria for approval as of December 1, 2025. Initial claims for oncology products will no longer be for 14-days’ supply, but instead subject to plan limitations, quantity limits and prior authorization criteria taking effect January 1, 2026. For comprehensive, clinical criteria, please visit the TennCare/Optum Rx® website and scroll to find “PDL Criteria” under “Useful Links”. 

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

TennCare is continuing the process of reviewing all covered drug classes. Changes to the Preferred Drug List (PDL) occur as new classes are reviewed, and previously reviewed classes are revisited. As a result of these changes, some medications your patients are taking may be considered non-preferred agents in the future. Please inform your patients who are on these medications that switching to preferred products will decrease delays in receiving their medications. We encourage you to share this information with other TennCare providers. The individual changes to the PDL are listed below. The new PDL will be posted on January 1, 2026. For details on clinical criteria, please visit OptumRx/TennCare and click on “Criteria PDL” under “Useful Links”.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

The deadline to submit an attestation of low-volume status and proof of actual prescription volume to your contracted PBMs is December 1. Volume status is based on your pharmacy’s actual prescription volume from July 1, 2024, to June 30, 2025. For more information, please refer to the Department of Commerce and Insurance (TDCI) rules. The Tennessee Pharmacists Association’s PBM resource page also has some helpful information to assist you with this process.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.